Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease
Kiran Musunuru(University of Pennsylvania), Rebecca C. Ahrens‐Nicklas(Children's Hospital of Philadelphia), Shweta Sharma(Aldevron (United States)), Logan T. Hille(Harvard University), Taylor R. Hudson(Innovative Genomics Institute), Venkata S.K. Indurthi(Aldevron (United States)), Kate Keogh(Teagasc - The Irish Agriculture and Food Development Authority), Christina M. Wright(Children's Hospital of Philadelphia), Samantha Burke(Children's Hospital of Philadelphia), Garrett R. Rettig(Integrated DNA Technologies (United States)), Christian M. Brommel(Integrated DNA Technologies (United States)), Thomas F. Osborne(Integrated DNA Technologies (United States)), Julia Hacker(University of Pennsylvania), Petros Giannikopoulos(University of California, San Francisco), Fyodor D. Urnov(Innovative Genomics Institute), Ashley M. Jacobi(Integrated DNA Technologies (United States)), Christopher A. Vakulskas(Integrated DNA Technologies (United States)), Sean C. Semple(Arbutus Biopharma (Canada)), Sarah McCague(Children's Hospital of Philadelphia), Gavin Kurgan(Integrated DNA Technologies (United States)), Cathleen Lutz(Jackson Laboratory), Juliana C. Small(Children's Hospital of Philadelphia), Lindsey A. George(Children's Hospital of Philadelphia), Rachel A. Silverstein(Harvard University), Benjamin P. Kleinstiver(Harvard University), Sadik H. Kassim(Danaher (United States)), Anne Marie Berry(University of Pennsylvania), Kyle J. Kinney(University of Iowa), Ying K. Tam(Arbutus Biopharma (Canada)), David R. Liu(Broad Institute), Alvin Hsu(Broad Institute), Mohamad‐Gabriel Alameh(Children's Hospital of Philadelphia), Kevin Briseno(Innovative Genomics Institute), Sarah K. Bick(Vanderbilt University), Christopher Barbosa(Acuitas Therapeutics (Canada)), Ellen Schmaljohn(Integrated DNA Technologies (United States)), Xiao Wang(University of Pennsylvania), He Zhang(Shenyang Agricultural University), Kim T. Ng(Children's Hospital of Philadelphia), Sarah Grandinette(University of Pennsylvania), Nancy A. Robinson-Garvin(Children's Hospital of Philadelphia), Michael A. Collingwood(Integrated DNA Technologies (United States)), Michael Jepperson(Aldevron (United States)), Morgan Sturgeon(Integrated DNA Technologies (United States))
Cited by 272
Related Papers
High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effects
|Nature|2016|2.7k
CRISPResso2 provides accurate and rapid genome editing sequence analysis
|Nature Biotechnology|2019|1.8k
Rational design of cationic lipids for siRNA delivery
|Nature Biotechnology|2010|1.8k
Engineered CRISPR-Cas9 nucleases with altered PAM specificities
|Nature|2015|1.7k
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
|Nature Nanotechnology|2019|1.6k